Brief: Enanta Pharmaceuticals Receives FDA Fast Track Designation For EDP-323
06/04/2023 13:05
April 6 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION
FOR
EDP-323, ITS ORAL, L-PROTEIN INHIBITOR IN DEVELOPMENT FOR THE
TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS
Source text for Eikon: ID:nBwc40HQra
Further company coverage: ENTA.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates